We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

3 hedge funds and large institutions have $224K invested in XTL Biopharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% less funds holding

Funds holding: 5 → 3 (-2)

45% less capital invested

Capital invested by funds: $405K → $224K (-$181K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
3
Holders Change
-2
Holders Change %
-40%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$1.04K

Top Sellers

Rank Fund Capital Flow
1
U
UBS
Switzerland
-$4K
2
BRWA
B. Riley Wealth Advisors
Florida
-$1.22K
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
1
Invesco
Georgia
$221K – – –
TRCT
2
Tower Research Capital (TRC)
New York
$2K +$1.04K +20 +54%
Ameriprise
3
Ameriprise
Minnesota
$1K – – –
U
4
UBS
Switzerland
– -$4K -63 Closed
BRWA
5
B. Riley Wealth Advisors
Florida
– -$1.22K -20 Closed

XTLB Hedge Fund Activity: Q3 2014 in Review

3 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2014, worth a combined $224K — down 45% from $405K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of XTLB and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Tower Research Capital (TRC), adding an estimated $1.04K. The largest seller was UBS, exiting entirely with an estimated $4K sold.

  • 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2014, down from 5 in Q2 2014.
  • Funds reported $224K of XTL Biopharmaceuticals stock for Q3 2014, down 45% quarter-over-quarter.
  • 0 funds opened new XTL Biopharmaceuticals positions in Q3 2014 and 2 closed out, a net change of -2 holders.
  • The largest XTL Biopharmaceuticals buyer in Q3 2014 was Tower Research Capital (TRC), an estimated $1.04K added.
  • The largest XTL Biopharmaceuticals seller in Q3 2014 was UBS, an estimated $4K sold.

Based on aggregated 13F filings for Q3 2014.